Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

Reports Q3 revenue $17.7B, consensus $14.95B. Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We delivered another ...

Pfizer (NYSE:PFE) shares climbed around 2% in premarket trading Tuesday after the pharma giant raised earnings and revenue guidance for fiscal 2024 and beat Q3 results estimates.

The third-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s ... Lorbrena and Braftovi/Mektovi, and as we delivered ...

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

Lorbrena and Braftovi/Mektovi, and as we delivered on heightened demand for Paxlovid during the recent COVID-19 wave.” For the full fiscal 2024, Pfizer has raised its EPS guidance to a range of ...

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

Here are five top dividend stocks, including two Dividend Kings, that nervous investors should consider now for passive ...